ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.89+0.08 (+2.10%)
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
ARS Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
ARS Pharmaceuticals's cash was $138.35M at Sep 30, 2026. For fiscal 2025 it was $244.99M, down 22.0% from the year before. The highest annual figure on record is $314.02M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $244.99M | -22.0% |
| FY2024 | Dec 31, 2024 | $314.02M | +37.5% |
| FY2023 | Dec 31, 2023 | $228.36M | -16.8% |
| FY2022 | Dec 31, 2022 | $274.38M | +356.8% |
| FY2021 | Dec 31, 2021 | $60.06M | +144.9% |
| FY2020 | Dec 31, 2020 | $24.52M | +133.0% |
| FY2019 | Dec 31, 2019 | $10.53M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $138.35M | -52.0% |
| Q2 FY2026 | Jun 30, 2026 | $143.85M | -40.1% |
| Q1 FY2026 | Mar 31, 2026 | $200.97M | -27.1% |
| Q4 FY2025 | Dec 31, 2025 | $244.99M | -22.0% |
| Q3 FY2025 | Sep 30, 2025 | $288.21M | +40.8% |
| Q2 FY2025 | Jun 30, 2025 | $240.13M | +9.8% |
| Q1 FY2025 | Mar 31, 2025 | $275.73M | +23.3% |
| Q4 FY2024 | Dec 31, 2024 | $314.02M | +37.5% |
| Q3 FY2024 | Sep 30, 2024 | $204.62M | -15.4% |
| Q2 FY2024 | Jun 30, 2024 | $218.74M | -13.3% |
| Q1 FY2024 | Mar 31, 2024 | $223.63M | -15.5% |
| Q4 FY2023 | Dec 31, 2023 | $228.36M | -16.8% |
| Q3 FY2023 | Sep 30, 2023 | $241.90M | +140.2% |
| Q2 FY2023 | Jun 30, 2023 | $252.21M | +200.7% |
| Q1 FY2023 | Mar 31, 2023 | $264.55M | +267.1% |
| Q4 FY2022 | Dec 31, 2022 | $274.38M | +356.8% |
| Q3 FY2022 | Sep 30, 2022 | $100.72M | -66.5% |
| Q2 FY2022 | Jun 30, 2022 | $83.88M | -76.7% |
| Q1 FY2022 | Mar 31, 2022 | $72.07M | -80.8% |
| Q4 FY2021 | Dec 31, 2021 | $60.06M | +144.9% |
| Q3 FY2021 | Sep 30, 2021 | $301.01M | +110.7% |
| Q2 FY2021 | Jun 30, 2021 | $360.04M | +1074.1% |
| Q1 FY2021 | Mar 31, 2021 | $374.56M | +1449.0% |
| Q4 FY2020 | Dec 31, 2020 | $24.52M | +133.0% |
| Q3 FY2020 | Sep 30, 2020 | $142.87M | – |
| Q2 FY2020 | Jun 30, 2020 | $30.67M | – |
| Q1 FY2020 | Mar 31, 2020 | $24.18M | – |
| Q4 FY2019 | Dec 31, 2019 | $10.53M | – |
See a number that looks wrong?